How to access Ctexli for cerebrotendinous xanthomatosis from Bahrain: 2026 pathway via Salmaniya and cross-border referral | Reserve Meds
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-20.
Bahrain's metabolic-genetics depth sits at Salmaniya Medical Complex and King Hamad University Hospital for adult neurology, with paediatric cases captured at SMC paediatric neurology. The 2026 question is how to source Ctexli, the first FDA-approved oral chenodeoxycholic acid replacement for CTX.
Ask about Ctexli in Bahrain
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Why Ctexli, why now
Ctexli (chenodiol, chenodeoxycholic acid) received US FDA approval in February 2024 as the first labelled treatment for cerebrotendinous xanthomatosis (CTX) in adult and paediatric patients. Mirum Pharmaceuticals is the US sponsor. CTX is a rare autosomal recessive bile-acid synthesis disorder caused by biallelic pathogenic variants in CYP27A1, the gene encoding sterol 27-hydroxylase. The enzyme deficiency disrupts bile-acid synthesis and leads to accumulation of cholestanol and bile alcohols in tissues. Untreated CTX manifests with chronic diarrhoea, juvenile cataracts, tendon xanthomas, premature atherosclerosis, and progressive neurologic deterioration including cerebellar ataxia, pyramidal signs, dystonia, peripheral neuropathy, psychiatric features, and cognitive decline. Most patients develop neurologic symptoms in the second or third decade if untreated.
The 2026 question for a Bahrain patient with CTX is how to source Ctexli now that there is finally a labelled treatment. With FDA approval less than 24 months ago, Ctexli is not yet registered with the National Health Regulatory Authority (NHRA), so the pathway is named-patient personal-import authorisation under NHRA.
What Ctexli is, in plain language
Ctexli is an oral chenodiol capsule. Mechanistically it replaces the missing bile acid (chenodeoxycholic acid) and restores feedback suppression of the upstream cholesterol-to-bile-acid pathway, reducing the accumulation of cholestanol that drives tissue damage in CTX. Ctexli does not reverse pre-existing neurologic damage. It slows or halts progression, with strongest benefit when initiated before significant neurologic deterioration. Dosing is weight-based, given orally three times daily with food, lifelong.
Access pathway in Bahrain
Bahrain's National Health Regulatory Authority (NHRA) regulates medicine registration, import licensing, and pharmacovigilance under Law 38 of 2009 (Law of Practising the Profession of Pharmacy and Pharmacy Centres) and supporting regulations. Ctexli is not currently NHRA-registered. Access runs through the NHRA named-patient personal-import authorisation, filed by the treating clinician at Salmaniya Medical Complex (SMC) or King Hamad University Hospital (KHUH). Bahrain's metabolic-genetics depth sits at SMC and KHUH for adult neurology, with paediatric cases captured at SMC paediatric neurology.
The treating neurologist or metabolic specialist submits the named-patient import application documenting the biallelic CYP27A1 confirmation, elevated plasma cholestanol, neurological status, and requested dose and supply quantity. NHRA reviews and issues an import authorisation per shipment. Reserve Meds sources Ctexli from a US DSCSA-compliant specialty wholesaler or an EU-licensed supplier and arranges shipping to Bahrain International Airport.
Eligibility at a Bahrain neurology or metabolic clinic
Ctexli eligibility requires biallelic pathogenic variants in CYP27A1 on molecular genetic testing plus elevated plasma cholestanol (typically more than five-fold above the upper limit of normal). Genetic testing can be done locally at SMC or routed through KFSHRC Riyadh for confirmation. The treating clinician documents baseline neurological examination, MRI white-matter findings, baseline liver function, and any systemic features (tendon xanthomas, juvenile cataracts, chronic diarrhoea, premature atherosclerosis, psychiatric features). Adult neurology at SMC or KHUH manages confirmed cases; paediatric at SMC paediatric neurology.
Documentation required
The patient and physician should be prepared to provide: a current Bahraini CPR or passport; the molecular genetic report confirming biallelic CYP27A1 variants; recent plasma cholestanol levels; baseline neurological examination notes; recent brain MRI (with attention to dentate nucleus and white-matter signal); recent liver function tests; documentation of prior empiric chenodeoxycholic acid use, if any; the treating physician's prescription on hospital letterhead; the clinical justification letter; the NHRA named-patient import application; and evidence of payment capacity or insurance pre-authorisation. Reserve Meds prepares the US or EU export documentation, manufacturer pedigree, and customs packet.
Costs and funding considerations
Medicine price: quote on request. You get a written quote for your case before you commit. Pre-approval, CTX patients in the region were typically maintained on compounded chenodeoxycholic acid. Bahrain MoH coverage for rare-disease imports is case-by-case for Bahraini nationals with documented eligibility and neurological progression risk. Private insurance coverage for an unregistered ultra-orphan agent is unusual. Most families self-fund or co-fund.
Typical timeline
Weeks 0 to 4: confirm diagnosis (locally or via cross-border genetics), prescription preparation, NHRA import filing. Weeks 4 to 8: shipment arrival at Bahrain International Airport, initiation under neurology supervision, baseline labs documented. Weeks 8 to 24: cholestanol trend, liver function, tolerability monitoring. Months 6 and 12: full neurologic reassessment, repeat plasma cholestanol, and brain MRI white-matter assessment; cross-border review at KFSHRC.
When Ctexli is the wrong drug
Without biallelic CYP27A1 pathogenic variants, the diagnosis is not CTX and Ctexli is not indicated. Normal plasma cholestanol calls the CTX diagnosis into question; pursue alternative metabolic and neurogenetic workup. Advanced neurologic damage in untreated patients means the realistic goal is stabilisation rather than reversal; family counselling should reflect this. Pregnancy data are limited; contraception is required for women of childbearing potential. Significant hepatic dysfunction requires careful dose adjustment.
Frequently asked questions
- Is the pathway legal in Bahrain? Yes. It operates under NHRA named-patient personal-import authorisation under Law 38 of 2009.
- Will MoH or my insurance cover Ctexli? Bahraini nationals may secure MoH rare-disease case-by-case support; private insurance coverage for ultra-orphan agents is unusual.
- How long does treatment continue? Lifelong. CTX is a chronic genetic disease.
- Can I use generic chenodeoxycholic acid instead? Empirically yes in some jurisdictions, and many CTX patients were maintained on it pre-Ctexli; however, Ctexli is the FDA-approved labelled product with quality and supply assurance. The treating clinician decides.
- What if Ctexli is in short supply? Reserve Meds will inform you upfront and decline rather than promise a timeline we cannot deliver. We do not source from unverified channels.
- Can my child be treated? Yes; Ctexli is FDA-approved for paediatric patients. Paediatric cases in Bahrain are managed at SMC paediatric neurology.
Closing
Reserve Meds runs the Ctexli supply file from SMC or KHUH referral through NHRA named-patient authorisation, US or EU sourcing, and delivered Bahrain supply. Clinical decisions remain with your treating metabolic specialist or neurologist. To open a case, start your file in the patient portal or message us on WhatsApp; we will send a written quote for your case.
Illustrative example cases (composites, not real patients). This content is for general information and does not constitute medical advice. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating metabolic specialist or neurologist.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-20.
Frequently asked questions
How can I get Ctexli in Bahrain if it is not approved or available there?
Reserve Meds coordinates US-sourced Ctexli for patients in Bahrain through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for Bahrain and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Ctexli in Bahrain through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Ctexli. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in Bahrain, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Ctexli in Bahrain through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Ctexli to a patient in Bahrain?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Ctexli to your treating physician or hospital pharmacy in Bahrain, with appropriate handling for the product.
How long does it take, and what does Ctexli in Bahrain cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Ctexli in Bahrain?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.